These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 30557673)
1. Insurance Approval for Proton Beam Therapy and its Impact on Delays in Treatment. Gupta A; Khan AJ; Goyal S; Millevoi R; Elsebai N; Jabbour SK; Yue NJ; Haffty BG; Parikh RR Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):714-723. PubMed ID: 30557673 [TBL] [Abstract][Full Text] [Related]
2. The Insurance Approval Process for Proton Radiation Therapy: A Significant Barrier to Patient Care. Ning MS; Gomez DR; Shah AK; Kim CR; Palmer MB; Thaker NG; Grosshans DR; Liao Z; Chapman BV; Brooks ED; Tang C; Rosenthal DI; Garden AS; Frank SJ; Gunn GB Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):724-733. PubMed ID: 30557675 [TBL] [Abstract][Full Text] [Related]
3. Young Adult Populations Face Yet Another Barrier to Care With Insurers: Limited Access to Proton Therapy. Bishop AJ; Livingston JA; Ning MS; Valdez ID; Wages CA; McAleer MF; Paulino AC; Grosshans DR; Woodhouse KD; Tao R; Roth ME; Gunn GB; McGovern SL Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1496-1504. PubMed ID: 33677051 [TBL] [Abstract][Full Text] [Related]
4. Proton therapy expansion under current United States reimbursement models. Kerstiens J; Johnstone PA Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):235-40. PubMed ID: 24685152 [TBL] [Abstract][Full Text] [Related]
6. Patterns of Proton Beam Therapy Use in Clinical Practice between 2007 and 2019 in Korea. Lee SU; Yang K; Moon SH; Suh YG; Yoo GS Cancer Res Treat; 2021 Oct; 53(4):935-943. PubMed ID: 34015892 [TBL] [Abstract][Full Text] [Related]
7. Doing poorly by doing good: the bottom line of proton therapy for children. Johnstone PA; Kerstiens J J Am Coll Radiol; 2014 Oct; 11(10):995-7. PubMed ID: 24881504 [TBL] [Abstract][Full Text] [Related]
8. Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade. Do A; Mittal Y; Liapakis A; Cohen E; Chau H; Bertuccio C; Sapir D; Wright J; Eggers C; Drozd K; Ciarleglio M; Deng Y; Lim JK PLoS One; 2015; 10(8):e0135645. PubMed ID: 26312999 [TBL] [Abstract][Full Text] [Related]
9. Commercial Insurance Coverage of Advanced Radiation Therapy Techniques Compared With American Society for Radiation Oncology Model Policies. Verma V; Ludmir EB; Mesko SM; Brooks ED; Augustyn A; Milano MT; Lin SH; Chang JY; Welsh JW Pract Radiat Oncol; 2020; 10(5):324-329. PubMed ID: 31446147 [TBL] [Abstract][Full Text] [Related]
10. Three-Year Results of a Prospective Statewide Insurance Coverage Pilot for Proton Therapy: Stakeholder Collaboration Improves Patient Access to Care. Ning MS; Palmer MB; Shah AK; Chambers LC; Garlock LB; Melson BB; Frank SJ JCO Oncol Pract; 2020 Sep; 16(9):e966-e976. PubMed ID: 32302271 [TBL] [Abstract][Full Text] [Related]
11. Impact of a Step Therapy for Guanfacine Extended-Release on Medication Utilization and Health Care Expenditures Among Individuals Receiving Treatment for ADHD. Suehs BT; Sikirica V; Mudumby P; Dufour R; Patel NC J Manag Care Spec Pharm; 2015 Sep; 21(9):793-802, 802a-802i. PubMed ID: 26308226 [TBL] [Abstract][Full Text] [Related]
12. Ethical Allocation of Proton Therapy and the Insurance Review Process. Grzywacz V; Quinn TJ; Wilson T; Reitemeier P; Navin M; Hamstra D; Anderson J; Chinnaiyan P; Stevens C; Kabolizadeh P Pract Radiat Oncol; 2021; 11(5):e449-e458. PubMed ID: 33548544 [TBL] [Abstract][Full Text] [Related]
13. The impact of prior authorization review on orthopaedic subspecialty care: a prospective multicenter analysis. Jarrett CD; Dawes A; Abdelshahed M; Cil A; Denard P; Port J; Weinstein D; Wright MA; Bushnell BD J Shoulder Elbow Surg; 2024 Jun; 33(6):e336-e342. PubMed ID: 37993089 [TBL] [Abstract][Full Text] [Related]
14. Assessment of Proton Beam Therapy Use Among Patients With Newly Diagnosed Cancer in the US, 2004-2018. Nogueira LM; Jemal A; Yabroff KR; Efstathiou JA JAMA Netw Open; 2022 Apr; 5(4):e229025. PubMed ID: 35476066 [TBL] [Abstract][Full Text] [Related]
15. Strategic Operational Redesign for Successfully Navigating Prior Authorization Barriers at a Large-Volume Proton Therapy Center. Brooks ED; Ning MS; Palmer MB; Gunn GB; Frank SJ; Shah AK JCO Oncol Pract; 2020 Oct; 16(10):e1067-e1077. PubMed ID: 32639929 [TBL] [Abstract][Full Text] [Related]
16. Prior Authorization Leads to Administrative Burden and Delays in Treatment in Primary Total Joint Arthroplasty Patients. Lizcano JD; Goh GS; Tarabichi S; Krueger CA; Austin MS; Courtney PM J Arthroplasty; 2024 Sep; 39(9S2):S65-S70.e2. PubMed ID: 38493967 [TBL] [Abstract][Full Text] [Related]
17. Surgical Management of Diastasis Recti: A Systematic Review of Insurance Coverage in the United States. Rosen CM; Ngaage LM; Rada EM; Slezak S; Kavic S; Rasko Y Ann Plast Surg; 2019 Oct; 83(4):475-480. PubMed ID: 31524746 [TBL] [Abstract][Full Text] [Related]
18. Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population. Bergeson JG; Worley K; Louder A; Ward M; Graham J J Manag Care Pharm; 2013 Jun; 19(5):374-84. PubMed ID: 23697475 [TBL] [Abstract][Full Text] [Related]
19. Principles and reality of proton therapy treatment allocation. Bekelman JE; Asch DA; Tochner Z; Friedberg J; Vaughn DJ; Rash E; Raksowski K; Hahn SM Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):499-508. PubMed ID: 24798985 [TBL] [Abstract][Full Text] [Related]
20. Medications requiring prior authorization across health insurance plans. Jones LK; Ladd IG; Gionfriddo MR; Gregor C; Evans MA; Graham J Am J Health Syst Pharm; 2020 Apr; 77(8):644-648. PubMed ID: 32123921 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]